BioCryst Pharma (BCRX) Tops Q1 EPS by 7c ; Offers Guidance

BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of $0.00, $0.07 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $134.2 million versus the consensus estimate of $127.91 million.

GUIDANCE:

BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $563.6 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Warsh: Inflation Data Don’t Suggest Trend Meaningfully Improved
• Trump: will sign order to create U.S. Space Academy
• Baird on AECOM Technology (ACM): 'Underlying design demand, International margins, and market share gains remain good'